BRCA1 and ovarian carcinoma: Thus, our findings suggest that a combination of PARP inhibitor with SN-38 could cause extensive DNA damage and DNA replication stress, subsequently leading to cancer cell apoptosis, therefore sensitizing BRCA1/2-proficient ovarian cancer cells to PARP inhibitors.